Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etirinotecan pegol - JenKem Technology

Drug Profile

Etirinotecan pegol - JenKem Technology

Alternative Names: JK-1201l; PEG-irinotecan - JenKem; Pegylated irinotecan - 3SBio; Pegylated irinotecan - JenKem; SSS 22

Latest Information Update: 20 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JenKem Technology
  • Developer 3SBio; JenKem Technology
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 11 Nov 2021 Phase-I/II clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (IV) (NCT05158491)
  • 31 Mar 2021 JenKem Technology completes a phase I trial in in Solid tumours (Second-line therapy or greater) in China (NCT04366648)
  • 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in China (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top